Combined Transplantation of Unmanipulated Haploidentical and a SingleCord Blood Unit for Patients With Hematologic Malignancies
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Cord Blood Engraftment
Detectable cord blood engraftment should be present by day 100 in at least 50% of patients.
Andrew Artz, MD
University of Chicago
United States: Institutional Review Board
|University of Chicago||Chicago, Illinois 60637|